Review Article
Below are the latest Acta Pharmacologica Sinica articles published online ahead of print publication.
Currently no content available!
- Home /
- Home
New Impact Factor of APS rose to 4.010
The new Impact Factor of Acta Pharmacologica Sinica (APS) is 4.010 and the Total Cites is 8687 according to the Journal Citation Reports released June 20 by Clarivate Analytics. The Impact Factor ranking of APS has been promoted to a new record in the Pharmacology & Pharmacy journals (53rd/267, Q1) and the Multidisciplinary Chemistry journals (49th/172, Q2).
Under the leadership of the Editor-in-Chief Professor Jian Ding and the kind support from the Editorial Board members, APS achieved a great success in the journal developments. The steady growth of the impact factor demonstrates the increased recognition of APS in the field. ...
Importance of integrating nanotechnology with pharmacology and physiology for innovative drug delivery and therapy – an illustration with firsthand examples
Nanotechnology has been applied extensively in drug delivery to improve the therapeutic outcomes of various diseases. Tremendous efforts have been focused on the development of novel nanoparticles and delineation of the physicochemical properties of nanoparticles in relation to their biological fate and functions. However, in the design and evaluation of these nanotechnology-based drug delivery systems, ...
Emerging roles of sphingosylphosphorylcholine in modulating cardiovascular functions and diseases
Roles of sphingosylphosphorylcholine (SPC) in blood vessels. In normal vessels, the endothelium is intact. SPC acts on endothelial cellsand has protective effects on blood vessels. When the endothelium is injured, vascular smooth muscle cells (VSMCs) are exposed to SPC,which is harmful to blood vessels
Vascular endothelial dysfunction, a major mediator in diabetic cardiomyopathy
Diabetes mellitus is currently a major public health problem. A common complication of diabetes is cardiac dysfunction, which is recognized as a microvascular disease that leads to morbidity and mortality in diabetic patients. While ischemic events are commonly observed in diabetic patients, the risk for developing heart failure is also increased, independent of the severity of coronary artery disease and hypertension. This diabetes-associated clinical entity is considered a distinct disease process referred to as “diabetic cardiomyopathy” ...
Discovery and development of NA-1 for the treatment of acute ischemic stroke
Stroke creates a complex interplay of multiple signaing pathways including excitotoxicity, ionic imbalance, inflammation, oxidative stress and apoptosis. There are very few treatments that have been shown to be beneficial in acute stroke. Recent findings have provided insights into the pathophysiology and mechanisms of ischemic stroke, complementing the traditional glutamate hypothesis: the molecular interaction between PSD95 and GluN2B has been identified as a culprit in stroke-mediated excitotoxicity, leading to the discovery of NA-1, a peptide that disrupts that interaction, as a potent neuroprotective agent for the treatment of acute stroke. ...
Therapeutic gene editing: delivery and regulatory perspectives
Gene-editing technology is an emerging therapeutic modality for manipulating the eukaryotic genome by using target-sequence- speci c engineered nucleases. Because of the exceptional advantages that gene-editing technology offers in facilitating the accurate correction of sequences in a genome, gene editing-based therapy is being aggressively developed as a next-generation therapeutic approach to treat a wide range of diseases.
Programmable co-delivery of the immune checkpoint inhibitor NLG919 and chemotherapeutic doxorubicin via a redox-responsive immunostimulatory polymeric prodrug carrier
To achieve synergistic therapeutic ef cacy and prevent cancer relapse, chemotherapy and immunotherapy have been combined asa new modality for tumor treatment. In this work, we designed a redox-responsive immunostimulatory polymeric prodrug carrier, PSSN10, for programmable co-delivery of an immune checkpoint inhibitor NLG919 (NLG) and a chemotherapeutic doxorubicin (DOX).
CN 31-1347/R
ISSN 1671-4083
EISSN 1745-7254
Editor-in-Chief
2018 Impact Factor 4.010*
49/172 Chemistry, Multidisciplinary
53/267 Pharmacology & Pharmacy
*2019 Journal Citation Reports® Science Edition
Society Resources
Publishing Information
Acta Pharmacologica Sinica is published by SPRINGER NATURE
Membership
This journal is a member of and subscribes to the principles of the Committee on Publication Ethics.
